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Introduction: Management of pulmonary metastasis of non-small
cell lung cancer (NSCLC) remains controversial. We reviewed our
surgical treatment for pulmonary metastasis of NSCLC.
Methods: Seventy-six patients with pulmonary metastasis of
NSCLC underwent pulmonary resections in two institutes during the
past 10 years. Eighteen patients with simultaneous same lobe me-
tastasis as the primary lesion underwent mostly lobectomies. Sixteen
patients with simultaneous different lobe metastasis underwent com-
bined margin-free resections. Forty-nine pulmonary metastasecto-
mies were performed in 42 patients with recurrent lung cancer.
Overall survival and disease-free survival in each group were ex-
amined, and factors affecting survivals were investigated.
Results: In the patients with the same lobe metastasis 5-year
survival was 79.6%, and median and 5-year disease-free survivals
were 39.1 months and 41.3%. In the patients with simultaneous
different lobe metastasis median survival and 5-year survival were
37.7 months and 30.7%, and median and 5-year disease-free surviv-
als were 13.3 months and 12.5%, respectively. Multiple pulmonary
metastasis and mediastinal node metastasis were identified as sig-
nificant factors affecting survivals. In the patients with recurrent
pulmonary metastasis median survival and 5-year survival were 40.0
months and 34.8%, and median and 5-year disease-free survivals
were 23.7 months and 14.4%, respectively. Node metastasis, higher
age, and shorter interval from the prior resection were identified as
significant factors affecting survivals.
Conclusions: These findings suggest that the simultaneous same
lobe metastasis is under the same indication for the primary lesion,
and that the simultaneous different lobe metastasis and recurrent pul-
monary metastasis should be removed in selected patients.
Key Words: Non-small cell lung cancer, Surgery, Pulmonary me-
tastasis, Recurrence, Metastasectomy.
(J Thorac Oncol. 2009;4: 203–207)
Standard treatment for pulmonary metastasis of non-smallcell lung cancer (NSCLC) is not well defined. Simulta-
neous intralobar metastasis can be removed with an anatomic
resection when the primary lesion is indicated for surgical
treatment, resulting in a favorable outcome in the literature.1,2
Simultaneous different lobe metastasis of the lung cancer is
not indicated for resection in the current clinical guideline.3
Furthermore, surgical treatment for recurrent pulmonary me-
tastasis has been controversial.4 To reveal the outcome of
surgical treatment for pulmonary metastasis of NSCLC, we
reviewed our 10 years experience of pulmonary metastasec-
tomy of NSCLC.
PATIENTS AND METHODS
From 1997 to March 2007, 76 patients with pulmonary
metastasis of NSCLC underwent 83 pulmonary resections for
curative intent in two institutes, Kyoto University Hospital
and Gifu National Hospital, Japan. The indication for pre-
sumable pulmonary metastasectomy was a solitary or limited
number of pulmonary lesions, completely resectable, without
other organ metastasis, and tolerable for the surgery. During
the same period 1638 thoracotomies for primary lung cancer
were performed in the two institutes, indicating that the
resections of pulmonary metastasis were 5.1% of the surger-
ies for lung cancer. Fifty-eight patients were men and 25 were
women with the mean age of 65.9 years (ranging 40–83
years). Thirty-four patients had simultaneous pulmonary me-
tastases at the time of primary resection for lung cancer: 18
were in the same lobe as the primary lesion and 16 were in the
different lobe. Forty-nine patients had recurrent pulmonary
metastases after the previous pulmonary resection for lung
cancer. We also performed 28 pulmonary resections for
synchronous multiple lung cancers and 35 pulmonary resec-
tions for metachronous primary lung cancers during the
period. Diagnosis of pulmonary metastasis was based on the
pathologic findings; standard hematoxylin-eosin staining was
examined in all specimens and additional immunohistochem-
ical staining of p53 was mostly examined in the later period
of the study. Based on the similarity of morphology and
immunohistochemical staining, diagnosis of the pulmonary
metastasis was done by our pathologists. When the definitive
diagnosis was not obtained with the pathologic findings, the
criteria for diagnosis of multiple primary lung carcinoma by
Martini and Melamed5 was applied to differentiate metastasis
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from multiple primary lung cancer. When multiple pulmo-
nary nodules were identified pathologically similar, the larg-
est nodule was defined as the primary lesion and the other(s)
were defined as metastatic lesion(s). According to the lung
cancer staging system,6 the simultaneous same lobe metasta-
sis, different lobe metastasis, and metachronous pulmonary
metastasis were classified to T4-stage IIIB, M1-stage IV, and
recurrent lung cancer, respectively; therefore, we examined
these patients for survival analysis separately.
All eighteen patients with the simultaneous same lobe
metastasis were diagnosed after the pulmonary resection.
Histology was adenocarcinoma in 10, squamous cell carci-
noma in seven, and large cell carcinoma in one. Clinical
staging without additional nodes was stage 1A (T1N0) in five,
1B (T2N0) in eight, 2B (T2N1) in two, and 3A (T1–2N2) in
three. Surgical procedures were 16 lobectomies including one
sleeve lobectomy and two segmentectomies. All tumors were
completely removed. Pathologic node staging was N0 in 12,
N1 in two, and N2 in four. Sixteen patients had solitary
pulmonary metastasis and two patients had two metastatic
nodules in the same lobe. Eight patients received postopera-
tive intravenous platinum-based chemotherapy and six pa-
tients received postoperative uracil-tegafur (UFT) adminis-
tration, whereas seven patients did not receive any adjuvant
therapy.
Sixteen patients with the simultaneous different lobe
metastasis underwent combined pulmonary resections. Four
patients were clinically diagnosed as pulmonary metastasis
preoperatively, whereas the other patients were diagnosed
after the pulmonary resections. Histology was adenocarci-
noma in 12, squamous cell carcinoma in three, and large cell
neuroendocrine carcinoma in one. Clinical staging without
additional nodules was T1N0 in seven, T2N0 in three, T2N1
in one, T1N2 in two, and T2N2 in three. Surgical procedures
were 11 lobectomies with wedge resections/segmentecto-
mies, two segmentectomies with wedge resections, one bilo-
bectomy, and two pneumonectomies. All tumors were com-
pletely removed. Ten patients had ipsilateral lung metastasis
and six patients had contralateral lung metastasis. Thirteen
patients had solitary metastasis, and three patients had two
metastatic nodules, one of which was the same lobe metas-
tasis in each patient. Pathologic T-factor was T1 in seven, T2
in six, and T4 (pm 1) in three. Pathologic N-factor was N0 in
nine, N2 in five, and N3 in two. Four patients received
preoperative intravenous platinum-based chemotherapy. Nine
patients received postoperative intravenous chemotherapy
and four patients received UFT, whereas six patients did not
receive any postoperative chemotherapy.
Forty-nine pulmonary resections for recurrent pulmo-
nary metastasis were performed in 42 patients. Seven patients
underwent a repeated pulmonary metastasectomy for recur-
rence again. Histology of the recurrent lung cancer was
adenocarcinoma in 30 and squamous cell carcinoma in 19.
Thirty-nine resections were for solitary pulmonary lesion and
10 resections were for multiple (2  4) pulmonary lesions.
Staging of the lung cancer at the time of initial resection was
stage I in 25, stage II in seven, stage III in eight, and stage IV
in two. The interval from the prior pulmonary resection was
9.1 to 112 months (median 28.0 months). Surgical procedures
were essentially margin-free resections; 31 wedge resections,
10 segmentectomies with or without wedge resections, four
lobectomies including one sleeve lobectomy, and four com-
pletion pneumonectomies. Complete resection was obtained
in all patients except one who underwent a pneumonectomy
with cancer-positive bronchial stump. Lymph node metasta-
sis along with pulmonary metastasis was identified in four
patients. Three patients received preoperative intravenous
chemotherapy. Fifteen patients received postoperative intra-
venous chemotherapy and 14 patients received UFT, whereas
25 patients did not receive any postoperative therapy.
The survival and the date of tumor recurrence after the
pulmonary resection were examined in each patient. In the
patients with simultaneous pulmonary metastasis, overall
survival was defined as the duration from the pulmonary
resection to the last follow-up or the death with any reason,
and disease-free survival was defined as the duration from
pulmonary resection to the date of recurrence or the death
with any reason. In the patients with recurrent lung cancer,
overall survival was defined as the duration from the first
metastasectomy to the last follow-up or the death with any
reason, and disease-free survival was defined as the duration
from the each pulmonary resection to the date of recurrence
or the death with any reason. Continuous data are presented
as means, and categorical data are presented as exact num-
bers. Survival estimates were derived by Kaplan-Meier anal-
ysis. Factors including age, sex, histology, T and N factors,
number of pulmonary metastasis, operative procedure, and
adjuvant chemotherapy were analyzed. Stratified log-rank
analysis and Cox proportional-hazard modeling were used to
investigate and adjust for major prognostic and stratification
factors. A two-sided probability value of less than 0.05 was
considered statistically significant. The study was performed
in accordance with the Declaration of Helsinki. Kyoto Uni-
versity institutional review board approved this study and
waived the requirement for individual patient consent for this
retrospective study.
RESULTS
Overall Survival and Disease-Free Survival
Median follow-up of all patients was 29.6 months after
the resection of pulmonary metastasis. Forty-one patients
(53.9%) were completely followed until their death or more
than 5 years after the resection.
Overall survival curve and disease-free survival curve
of patients with the same lobe metastases are shown in Figure
1. The 5-year survival rate was 79.6%. Median disease-free
survival was 39.1 months and the 5-year disease-free survival
rate was 41.3%. Overall survival curve and disease-free
survival curve of patients with the different lobe metastasis
are shown in Figure 2. Median survival was 37.7 months and
the 5-year survival rate was 30.7%. Median disease-free
survival was 13.3 months and the 5-year disease-free survival
rate was 12.5%. Overall survival curve and disease-free
survival curve of 42 patients with recurrent pulmonary me-
tastasis are shown in Figure 3. Median survival was 40.0
months and the 5-year survival rate was 34.8%. Median
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disease-free survival was 23.7 months and the 5-year dis-
ease-free survival rate was 14.4%. Between the first me-
tastasectomy (n  42) and remetastasectomy (n  7), no
significant difference was seen in the disease-free survivals
(Figure 4).
Prognostic Factors Affecting Survivals
In the patients with the simultaneous same lobe metas-
tasis, statistical analyses identified no significant factors af-
fecting overall survival or disease-free survival. In the pa-
tients with the simultaneous different lobe metastasis, the
proportional hazards model showed multiple pulmonary me-
tastases as a significant factor in overall survival, and medi-
astinal node metastasis as a significant factor in disease-free
survival (Table 1). In the patients with recurrent pulmonary
metastasis, the age of 70 years or more and node metastasis
were identified as significant factors affecting overall sur-
vival, and the shorter interval from the prior resection was
identified as a factor affecting disease-free survival (Table 2).
DISCUSSION
Pulmonary metastasis of NSCLC is differently staged
with regard to the time, simultaneous or metachronous, and
the location associated with the primary lesion. In the current
tumor, node, metastasis staging system revised in 19976
simultaneous same lobe metastasis as the primary lesion (pm
1) is classified as T4—stage IIIB when distant metastasis is
excluded. Simultaneous different lobe metastasis from the
primary lesion (pm2) is classified as M1-stage IV disease.
Metachronous pulmonary metastasis after the resection of
primary lung cancer is a recurrent disease and the treatment
for the recurrence depends on the number and the site.
Surgical treatment for simultaneous pulmonary metastasis of
NSCLC occasionally resulted in a favorable prognosis in the
literature1,2; however, the efficacy of the pulmonary resection
for recurrent disease remains controversial.
Surgical procedure for pulmonary metastasis is the
margin-free resection. The satellite lesion in the same lobe is
removed with a lobectomy or a larger anatomic resection
indicated for the primary lesion. For simultaneous different
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FIGURE 1. Kaplan-Meier survival curves of patients with
simultaneous same lobe metastasis. Solid and dashed lines
represent the overall survival and the disease-free survival
(overall 5-year survival: 79.6%, median and 5-year disease-
free survivals: 39.1 months and 41.3%, respectively).
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FIGURE 2. Kaplan-Meier survival curves of patients with
simultaneous different lobe metastasis. Solid and dashed
lines represent the overall survival and disease-free survival
(median and 5-year overall survivals: 37.7 months and
30.7%, median and 5-year disease free survivals: 13.3
months and 12.5%, respectively).
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FIGURE 3. Kaplan-Meier survival curves of patients with
recurrent pulmonary metastasis. Solid and dashed lines rep-
resent the overall survival and disease-free survival (median
and 5-year overall survivals: 40.0 months and 34.8%, me-
dian and 5-year disease free survivals: 23.7 months and
14.4%, respectively).
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FIGURE 4. Kaplan-Meier disease-free survival curves of pa-
tients with recurrent pulmonary metastasis. Solid and dashed
lines represent the first metastasectomy and remetastasec-
tomy. No significant difference was seen between the dis-
ease-free survivals.
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lobe metastasis or recurrent pulmonary metastasis, wedge
resection is usually applied. When the tumor is located
centrally close to a bronchus or pulmonary vessel or free
margin is difficult to obtain with wedge resection, an ana-
tomic resection such as segmentectomy or lobectomy is
required. When the tumor is large enough to occupy one lung
or invades a main bronchus, a pneumonectomy is applied for
few patients.
In this retrospective study, we sought to clarify the role
of pulmonary metastasectomy. Although the indications of
pulmonary resections, such as the number of nodules, node
status, and the site of lesion, were not identical throughout the
study, we examined these factors in survivals with the pro-
portional hazards model. We examined not only the survival
after the pulmonary resection but also the disease-free sur-
vival, which most previous reports of pulmonary metastasec-
tomy did not examine, to investigate the exact role of surgery.
Recent advances in chemotherapy for unresectable lung can-
cer should have improved prognosis even after recurrence.
Our result of pulmonary resection for the same lobe
metastasis as the primary lesion showed as high as 79.6% of
5-year survival rate although the disease-free survival was
lower. This attests the previous reports of favorable prognosis
after the pulmonary resection for simultaneous intralobar
metastasis of lung cancer. Bryant et al.7 reported a 5-year
survival of 57% in 26 patients with lung cancer of T4
(satellite) N0, 87% of whom underwent complete resection
and 73% of whom received adjuvant therapy. Osaki et al.8
reported a 5-year survival of 26.7% in 36 patients with
T4-satellite, 55.6% of whom had nodal metastasis, 91.7% of
whom underwent complete resection, and 41.7% of whom
received adjuvant therapy. Nakagawa et al.9 demonstrated
that the 5-year survival in 31 patients with T4-satellite and
some node metastasis was 39% after pulmonary resection.
The discrepancy of the survival rates in the reports including
current study may be explained by the differences in the rates
of complete resection, the nodal staging, and the adjuvant
therapy. Recently, the International Association for the Study
of Lung Cancer (IASLC) Lung Cancer Staging Project re-
ported pT4N0-additional nodule(s) in the same lobe (n 
363) had a 5-year survival rate of 28% and proposed to
classify this stage as T3.10 Patients with intralobar pulmonary
metastasis would have the same indication as that for the
primary lesion.
Resection for the simultaneous different lobe metastasis
is controversial in the literature.11–13 Nakagawa et al.9 re-
ported a 5-year survival of 19.3% in 17 patients with ipsilat-
eral different lobe metastasis after pulmonary resection.
Okada et al.14 reported a 5-year survival of 23.4% in 41
patients with ipsilateral different lobe metastasis, and that N0
TABLE 1. Multivariate Analysis of Patients with Simultaneous Different Lobe Metastasis
Variable
Overall Survival Disease-Free Survival
HR 95% CI p HR 95% CI p
Male/female 1.202 0.119–12.179 0.877 2.064 0.235–18.014 0.513
Age 70/70 13.821 0.484–394.597 0.125 3.424 0.549–21.375 0.188
Adenocarcinoma/others 0.367 0.006–23.489 0.637 0.243 0.019–3.112 0.277
Contralateral/ipsilateral 0.165 0.005–5.214 0.307 0.173 0.015–1.967 0.157
Pneumonectomy/lobectomy/
lesser resection
1.257 0.090–17.539 0.865 3.774 0.236–60.401 0.348
No. of metastasis 14.023 1.195–164.565 0.036 4.685 0.571–38.458 0.151
Mediastinal node metastasis 3.496 0.943–12.967 0.061 2.885 1.231–6.763 0.015
Adjuvant therapy 2.856 0.156–52.417 0.480 1.068 0.133–8.579 0.951
CI, confidence interval; HR, hazard ratio.
TABLE 2. Multivariate Analysis of Patients with Recurrent Pulmonary Metastasis
Variable
Overall Survival Disease-Free Survival
HR 95% CI p HR 95% CI p
Male/female 0.860 0.130–5.689 0.876 1.425 0.441–4.610 0.554
Age 70/70 6.642 1.599–27.579 0.009 1.880 0.730–4.845 0.191
Ad/Sq 0.924 0.236–3.627 0.910 1.582 0.623–4.019 0.335
No. of metastasis 4.807 0.882–26.198 0.070 1.909 0.727–5.011 0.189
Node metastasis Procedure 16.097 2.355–110.031 0.005 3.568 0.853–14.930 0.082
Pneumonectomy/
lesser resection
3.743 0.453–30.919 0.221 0.488 0.104–2.300 0.364
Adjuvant therapy 0.737 0.406–1.341 0.318 1.136 0.741–1.742 0.558
Interval from prior resection 0.967 0.930–1.005 0.091 0.963 0.930–0.998 0.041
Redo/first metastasectomy — — — 0.384 0.091–1.615 0.191
CI, confidence interval; HR, hazard ratio.
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and N1 diseases were significantly better than N2 and N3
diseases. Okumura et al.15 showed a 5-year survival of 11%
in 18 patients with different lobe metastasis and no significant
differences among T or N factors. These studies were con-
ducted retrospectively and in relatively small number of
patients, which may explain the differences in the results. The
IASLC Lung Cancer Staging Project reported 5-year survival
of the patients with ipsilateral pulmonary nodules in nonpri-
mary lobe (n  180) was 22% and proposed to classify as
T4.10 On the contrary, the IASLC Lung Cancer Project
reported additional nodules in the contralateral lung showed
a 5-year survival rate of 3%.16 In the latter analysis, surgery
was precluded, and it was not possible to differentiate be-
tween single and multiple lesions. Current study has the
strength of showing disease-free survival as well. Our result
of the pulmonary resection for simultaneous different lobe
metastasis showed the 5-year survival of 30.7% and median
survival of 37.7 months, however, median disease-free sur-
vival was 13.3 months. The difference between the median
survival and the median disease-free survival of 24.4 months,
about two thirds of the overall survival, might have been
provided by postrecurrent chemotherapy. In fact most of our
patients with postoperative recurrence received chemother-
apy as long as they were tolerable for it. Multiple pulmonary
metastases and mediastinal node involvement were identified
as poor prognostic factors in survivals. The efficacy of sur-
gical therapy for patients with different lobe metastasis is
limited when the pulmonary metastasis is solitary or preop-
eratively unproven.
Objective evidence supporting the role of surgery for
recurrent lung cancer is limited. Walsh et al.17 demonstrated
that complete resection or high-dose radiotherapy with cura-
tive intent significantly prolonged postrecurrent survival in
NSCLC. Sugimura et al.4 reported that surgical treatment for
23 patients with recurrent lung cancer confined in only lung
resulted in median survival of 32.8 months. Uncertainty
exists in differentiating a second primary lung cancer from
recurrent lung cancer. Surgical resection is frequently pre-
ferred for a solitary metachronous lung cancer, with a 5-year
survival of 26 to 33.4%.18–20 Our study showed median
survival and median disease-free survival of 40.0 months and
23.7 months, respectively, and the 5-year survival rate of
34.8%, which are comparable with these results. In the
analysis of prognostic factors higher age and concomitant
node metastasis significantly affected the overall survival and
the shorter interval from the prior pulmonary resection af-
fected the disease-free survival. Median duration from the
previous pulmonary resection was 28 months; in addition, the
patients with the duration of less than 2 years showed signif-
icantly shorter disease-free survival than those of more than 2
years (p 0.039). These results indicate that rapid recurrence
can be predicted with the clinical course before the resection.
Pulmonary metastasectomy for recurrent lung cancer can be
beneficial for younger patients with limited number of pul-
monary nodules, when the interval from the previous pulmo-
nary resection is 2 years or longer. Repeated pulmonary
metastasectomy can be considered under the same indication.
In conclusion, simultaneous same lobe metastasis of
NSCLC can be removed with an anatomic resection, resulting
in favorable prognosis; however, the efficacy of the resection
for simultaneous different lobe metastasis is limited. Pulmo-
nary metastasectomy can be a therapeutic option in selective
patients with recurrent lung cancer.
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